Koninklijke KPN NV (0O8F)
London Exchange · UK · prices in EUR · close of 20 Oct 2026
Key indicators
| Last close | EUR 4.087 |
|---|---|
| 52-week range | 3.598 – 4.793 |
| Return, 1 month / 3 months | +0.5% / −1.8% |
| Return, 1 year / 3 years | +4.3% / +50.7% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 19.0% |
| Worst drawdown (1 year) | -16.9% |
| Average daily value traded | 16.01M EUR |
| Dividend yield | 4.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Koninklijke KPN is a Dutch telecommunications company based in Rotterdam. It provides fixed-line and mobile telephony, broadband internet and television to households, and offers network, connectivity and information technology services to business and wholesale customers. KPN operates the national copper and fibre access networks in the Netherlands and sells bundled communications packages to consumers and organisations across the country.
Koninklijke KPN NV trades under the code 0O8F on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Koninklijke KPN NV (0O8F) trades on the London Exchange in UK. It last closed at EUR 4.087 on 20 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,314 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 4.3% and over the last three months it fell 1.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 43 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.6% | ||
| From 52-week high | -12.5% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -1.8% | ||
| 6-month return | -9.9% | ||
| 12-month return, skipping the last month | 3.8% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 19.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.9% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 16.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +4.9% |
|---|---|
| 1 month | +0.5% |
| 3 months | −1.8% |
| 6 months | −9.9% |
| 1 year | +4.3% |
| 3 years | +50.7% |
| 5 years | +87.3% |
Signals
| 50-day / 200-day average | 4.036 / 4.241 |
|---|---|
| Golden / death cross (60 days) | Death, 44 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.076 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Jul 2026 | EUR 0.0800 |
| 17 Apr 2026 | EUR 0.1090 |
| 25 Jul 2025 | EUR 0.0730 |
| 22 Apr 2025 | EUR 0.1020 |
| 26 Jul 2024 | EUR 0.0680 |
| 19 Apr 2024 | EUR 0.0980 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.